Eugenio Morelli

18PUBLICATIONS
129CO-AUTHORS
Medical infection agents (incl. prions)Molecular targetsGene and molecular therapyMicroelectromechanical systems (MEMS)Medical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Aug 04, 2026
DRP1-mediated mitochondrial fragmentation is a druggable vulnerability in multiple myeloma.

|Jul 29, 2026
A first-in-class RNA degrader reduces c-MYC expression and myeloma cell survival in preclinical models.

|Jun 09, 2026
CRISPR application in hematological disorders: from bench to bedside.

|May 13, 2026
MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma.

|Oct 17, 2025
ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3.

Mariateresa Fulciniti, Yao Yao, Tommaso Perini

|May 22, 2025
CRISPR-Cas13d functional transcriptomics reveals widespread isoform-selective cancer dependencies on lncRNAs.

Eugenio Morelli, Anil Aktas-Samur, Domenico Maisano

Pageof 3

Frequent Collaborators

6 joint publications

Anil Aktas-Samur

4 joint publications

Marcello Turi

4 joint publications

Mehmet Samur

4 joint publications

Annamaria Gulla